Patent intelligence · US
US 12371434
MLL1 inhibitors and anti-cancer agents
MLL1 inhibitors and anti-cancer agents
Patent details — US 12371434
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 29, 2025
- Expiration
- Jul 24, 2045
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/52, A61K31/53
Quick answer
US 12371434 (MLL1 inhibitors and anti-cancer agents) is held by CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/52, A61K31/53, A61K45/06, A61P
More from CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12427137
Method for reducing methane production in animal stomach
granted -
US 12421269
SGLT2/DPP4 inhibitor and application thereof
granted -
US 12403167
Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament
granted -
US 12397034
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12383535
Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
granted -
US 12378241
Pyridine derivative as FGFR and VEGFR dual inhibitors
granted
Frequently asked questions
What is US patent 12371434?
US 12371434 (MLL1 inhibitors and anti-cancer agents) is held by CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12371434?
CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 335 pharmaceutical patents for this assignee.
When does US 12371434 expire?
Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.